Navigation Links
BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers
Date:1/11/2011

ct which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Other product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in clinical development for the treatment of MPS IVA, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking StatementThis press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the expectations of the development of BMN 673, including the timing of the clinical trials of the candidate, and the possible efficacy of such candidate. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities, results and timing of current and planned clinical and preclinical studies related to such product; our ability to successfully manufacture the product; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2009 Annual Report on Form 10-K, and the factors contained in Bio
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BioMarin to Present at the J.P. Morgan 29th Annual Healthcare Conference
2. BioMarin to Present at the Deutsche Bank 2010 BioFEST Conference
3. BioMarin Completes Partial Exchange of Convertible Notes Due 2013 for Common Stock
4. BioMarin Announces Third Quarter 2010 Financial Results
5. BioMarin to Host a Research and Development Day on October 19th
6. BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
7. BioMarin to Present at the UBS Global Life Sciences Conference
8. BioMarin to Present at the Stifel Nicolaus Healthcare Conference
9. BioMarin Receives Orphan Drug Designation from the FDA for BMN-701 for the Treatment of Pompe Disease
10. BioMarin Acquires ZyStor Therapeutics, Inc.
11. BioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015  The Partnership to Fight Chronic Disease (PFCD) released a public ... and a new study analyzing the impact of increased cost sharing ... coalition working to educate policy makers and the public on the ... focused on how the Iowa healthcare exchange ...
(Date:1/23/2015)... and DUBLIN , Jan. 23, 2015 ... with KRS Global Biotechnology, Inc. for the compounding, packaging and ... for shipment in the United States . ... Outsourcing Facility capable of compounding naltrexone tablets in various strengths ...
(Date:1/23/2015)... 23, 2015  iMD Companies, Inc. (ICBU) has repositioned itself as ... and grab a foothold in the hydroponic, hemp and medical ... a presence in the sector, and recently partnering with the ... hemp and medical marijuana, iMD is committing to bring its ...
Breaking Medicine Technology:New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2
... ORLEANS, June 16 Cardinal Health, a,global provider ... and,productivity of health care, today announced that it ... (PET),radiopharmaceuticals for clinical trials., The company,s new ... at the Society of Nuclear Medicine,s (SNM) 55th ...
... the efficacy of RESPeRATE while highlighting ... BERLIN and NEW YORK, June 16 European Society ... Ltd., a medical device,company publicly traded on the Tel-Aviv ... studies and analysis highlighting RESPeRATE,-- the only medical device ...
Cached Medicine Technology:Cardinal Health Expands PET Nuclear Pharmacy Services to Support Clinical Drug Trials 2Blood Pressure Lowering Effect of Hypertension Treatment Device Further Validated in New Studies 2Blood Pressure Lowering Effect of Hypertension Treatment Device Further Validated in New Studies 3Blood Pressure Lowering Effect of Hypertension Treatment Device Further Validated in New Studies 4
(Date:1/22/2015)... York (PRWEB) January 22, 2015 The federal ... in the U.S. District Court, Southern District of West Virginia ... Inc. in that proceeding’s first bellwether trial. In an Order ... a new trial after finding that C.R. Bard had not ...
(Date:1/22/2015)... has released a new blog post explaining the main features ... , Auto insurance quotes help many drivers find the best ... call an agent or visit an agency for price information. ... http://autocarinsurancebest.com/ . , Every business who relies heavily on ...
(Date:1/22/2015)... NY (PRWEB) January 22, 2015 ... of Sports Medicine flagship journal Medicine & Science ... L-Citrulline before exercise may help reduce gastrointestinal (GI) ... 1 , Participants in the double-blind, placebo-controlled ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Four years since the ... – which coincided with the marriage of Avasa & Matthew Love ... ROAD, which is scheduled for release through White Swan Records on ... that there is a sacred path available to all of us ...
(Date:1/22/2015)... JJsHouse.com is a famous dress online store ... announces its latest collection of wedding dresses , and ... issue is the wedding dress on your big day; the ... life. Every bride wants to find the most suitable wedding ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUN ... Company Exclusive Group Ltd. (Alkaloida), has extended the Expiration ... all outstanding Ordinary Shares of Taro Pharmaceutical Industries Ltd. ... p.m., New York City time, on Friday, April 3, ...
... cognitive disorders, researchers say , , FRIDAY, March 20 ... "the edge of chaos," at a critical point ... who said their finding could help improve understanding ... The researchers used medical imaging to measure changes ...
... some groups, survival odds after angioplasty are not as ... major international study pinpoints which people with major heart ... than artery-opening angioplasty. , "Bypass surgery is preferable for ... Hlatky, professor of health research and policy and cardiovascular ...
... - Mayo Clinic research shows a correlation between inadequate ... taken by patients who have chronic pain. This correlation ... to treat chronic pain. According to the Centers for ... cause of disability in the United States. These patients ...
... Lead to a New Definition of ,Bedside Manner,WASHINGTON and ... Health Resource Center (NWHRC) just released the latest issue ... "Women & Health Care Reform." The report coincides ... effort to gain support and awareness of the need ...
... N.C., March 20 The Government of Kenya ... 870 health workers contracted over the past three ... the country,s severe shortage of health professionals.Designed to ... public health facilities using a private-sector outsourcing mechanism, ...
Cached Medicine News:Health News:Sun Pharmaceutical Extends Tender Offer for Taro 2Health News:Sun Pharmaceutical Extends Tender Offer for Taro 3Health News:Diabetics and Elderly May Fare Better With Bypass 2Health News:Diabetics and Elderly May Fare Better With Bypass 3Health News:Mayo Clinic Study Suggests Those Who Have Chronic Pain May Need to Assess Vitamin D Status 2Health News:Mayo Clinic Study Suggests Those Who Have Chronic Pain May Need to Assess Vitamin D Status 3Health News:National Women's Health Report Addresses Issues of Uninsured Plus New Paradigms of Care 2Health News:Kenya Government Appoints Emergency Health Workers to Permanent Positions 2Health News:Kenya Government Appoints Emergency Health Workers to Permanent Positions 3
The Microny pacemakers are among the smallest devices in the world. The Microny II SR+ pacemaker is the world's smallest, single-chamber rate-responsive pulse generator. The Microny pacemakers featur...
... family of pacemakers features several ... truly automatic devices in today's ... unparalleled combination of automated features ... builds on the popular and ...
... family, which includes the world's ... with the most advanced pacemaker ... AF Suppression™ algorithm, the first ... algorithm designed to suppress atrial ...
... Affinity pacemaker family offers ... truly automatic devices. Featuring ... of advanced technologies ever ... pacemaker incorporates the exclusive ...
Medicine Products: